Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Comment by pericles1on May 13, 2010 11:01am
410 Views
Post# 17094643

RE: RE: RE: RE: RE: RE: Reflections on meeting.

RE: RE: RE: RE: RE: RE: Reflections on meeting. 

I get a kick out of the other boards on V2 and Yahoo, Brad must have done a good job because the rose colored glasses are being passed out. Belgium is still not on board yet but the reformulation is the reason we are delayed, Ya!

I think they just want to kiss Vermorken's butt  so that's their explanation. Now if they had said that Belgium had screwing them up so they decided to wait for the reformulation, I would believe that.  Also at the meeting nobody challenged Brad on the enrollment problems. I still say that 14 patients in the confirmation H&N trial should have been done six months ago, it's pathetic. He claimed he does not have results on the NSCLC trial even though it is open label and they have learned interium results a number of times in the past, I don't believe that either. He sounds more confident than I have ever heard him and it comes across as bravado to me. Don't get me wrong I'm sticking around but their was not much meat in that presentation just mostly fluff!
Bullboard Posts